Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Clinical characteristics, disease activity and treatment of RA patients

From: Association between severity of periodontitis and clinical activity in rheumatoid arthritis patients: a case–control study

  N %
Gender
 Female 147 78.61
 Male 40 21.39
Mean (SD) age (years) 54.4 (10.8)  
Mean (SD) time evolution (years) 8.88 (7.32)  
 Early RA 35 18.72
 Established RA 152 81.28
Rheumatoid factor
 Seropositive 138 74.19
Rheumatoid factor concentration (IU/ml)
 Low (≤ 90) 49 36.84
 Moderate (91–300) 56 42.11
 High (> 300) 28 21.05
Anti-CCP
 Positive 114 67.86
Anti-CCP concentration (U/ml)
 Low (≤ 75) 30 27.27
 Moderate (76–300) 43 39.09
 High (> 300) 37 33.64
Level of activity, mean (SD)
 DAS28 3.81(1.31)  
 DAS28-CRP 3.18(1.18)  
 SDAI 14.49(10.74)  
 CDAI 12.68(10.19)  
Disease activity (combined index)
 Remission 38 20.32
 Low 39 20.90
 Moderate 85 45.45
 High 25 13.43
HAQ 0.760 (0.62)  
Glucocorticoid therapy
 No glucocorticoids 99 52.94
 Glucocorticoids 88 47.06
 Current dosage GC, mean (SD) (mg/day) 2.85 (4.24)  
  Low < 7.5 65 73.86
  Moderate 7.5–20 22 25
  High > 20 1 1.14
Type of RA therapy
 No treatment 10 5.35
 sDMARDs 99 52.94
  ≥ 2 sDMARDs 22 11.76
 bDMARDs 56 29.95
  1. Data represent number, percentage or mean (SD)
  2. anti-CCP anti-cyclic citrullinated peptide, bDMARD biologic disease-modifying antirheumatic drug, CDAI Clinical Disease Activity Index, DAS28 28-joint Disease Activity Score with erythrocyte sedimentation rate, DAS28-CRP 28-joint Disease Activity Score with C-reactive protein, GC corticosteroids, HAQ Health Assessment Questionnaire, RA rheumatoid arthritis, SD standard deviation, SDAI Simplified Disease Activity Index, sDMARD synthetic disease-modifying antirheumatic drug